Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 2919

1.

Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer.

Tewari KS, Burger RA, Enserro D, Norquist BM, Swisher EM, Brady MF, Bookman MA, Fleming GF, Huang H, Homesley HD, Fowler JM, Greer BE, Boente M, Liang SX, Ye C, Bais C, Randall LM, Chan JK, Ferriss JS, Coleman RL, Aghajanian C, Herzog TJ, DiSaia PJ, Copeland LJ, Mannel RS, Birrer MJ, Monk BJ.

J Clin Oncol. 2019 Jun 19:JCO1901009. doi: 10.1200/JCO.19.01009. [Epub ahead of print]

PMID:
31216226
2.

EXPRESS: Oral treprostinil use in children - a multi-center, observational experience.

Kanaan U, Varghese N, Coleman R, Huckaby J, Lawrence P, Jorgensen L, Miller-Reed K, Day R, Mallory G, Ivy DD.

Pulm Circ. 2019 Jun 19:2045894019862138. doi: 10.1177/2045894019862138. [Epub ahead of print] No abstract available.

PMID:
31215346
3.

Estimation of Actual and Ideal Bodyweight Using Morphometric Measurements of Miniature, Saddle-Type, and Thoroughbred Horses.

Catalano DN, Coleman RJ, Hathaway MR, Neu AE, Wagner EL, Tyler PJ, McCue ME, Martinson KL.

J Equine Vet Sci. 2019 Jul;78:117-122. doi: 10.1016/j.jevs.2019.04.008. Epub 2019 May 13.

PMID:
31203974
4.

The effect of articular cartilage focal defect size and location in whole knee biomechanics models.

Marchi BC, Arruda EM, Coleman R.

J Biomech Eng. 2019 Jun 15. doi: 10.1115/1.4044032. [Epub ahead of print]

PMID:
31201745
5.

Adaptive responses in a PARP inhibitor window of opportunity trial illustrate limited functional interlesional heterogeneity and potential combination therapy options.

Labrie M, Kim TB, Ju Z, Lee S, Zhao W, Fang Y, Lu Y, Chen K, Ramirez P, Frumovitz M, Meyer L, Fleming ND, Sood AK, Coleman RL, Mills GB, Westin SN.

Oncotarget. 2019 May 28;10(37):3533-3546. doi: 10.18632/oncotarget.26947. eCollection 2019 May 28.

6.

Understanding spatiotemporal variability of in-stream water quality in urban environments - A case study of Melbourne, Australia.

Shi B, Bach PM, Lintern A, Zhang K, Coleman RA, Metzeling L, McCarthy DT, Deletic A.

J Environ Manage. 2019 Jun 6;246:203-213. doi: 10.1016/j.jenvman.2019.06.006. [Epub ahead of print]

PMID:
31176982
7.

The plus maze and scototaxis test are not valid behavioral assays for anxiety assessment in the South African clawed frog.

Coleman RB, Aguirre K, Spiegel HP, Pecos C, Carr JA, Harris BN.

J Comp Physiol A Neuroethol Sens Neural Behav Physiol. 2019 May 29. doi: 10.1007/s00359-019-01351-3. [Epub ahead of print]

PMID:
31144017
8.

Equine Fecal Microbiota Changes Associated With Anthelmintic Administration.

Kunz IGZ, Reed KJ, Metcalf JL, Hassel DM, Coleman RJ, Hess TM, Coleman SJ.

J Equine Vet Sci. 2019 Jun;77:98-106. doi: 10.1016/j.jevs.2019.01.018. Epub 2019 Feb 13.

PMID:
31133326
9.

Advancing Drug Development in Gynecologic Malignancies.

Beaver JA, Coleman RL, Arend RC, Armstrong DK, Bala S, Mills GB, Sood AK, Herzog TJ.

Clin Cancer Res. 2019 May 24. pii: clincanres.0619.2019. doi: 10.1158/1078-0432.CCR-19-0619. [Epub ahead of print]

PMID:
31126961
10.

Life-history characteristics of an exploited bonefish Albula glossodonta population in a remote South Pacific Atoll.

Filous A, Lennox RJ, Coleman RR, Friedlander AM, Clua EEG, Danylchuk AJ.

J Fish Biol. 2019 May 22. doi: 10.1111/jfb.14057. [Epub ahead of print]

PMID:
31119738
11.

Poly-ADP-ribose polymerase inhibitor use in ovarian cancer: expanding indications and novel combination strategies.

Hinchcliff E, Westin SN, Dal Molin G, LaFargue CJ, Coleman RL.

Int J Gynecol Cancer. 2019 May 22. pii: ijgc-2019-000499. doi: 10.1136/ijgc-2019-000499. [Epub ahead of print]

PMID:
31118216
12.

Identifying markers of immune response in ovarian cancer: does PD-L1 expression meet the mark?

Gaillard SL, Coleman RL.

Ann Oncol. 2019 May 21. pii: mdz166. doi: 10.1093/annonc/mdz166. [Epub ahead of print] No abstract available.

PMID:
31111866
13.

Implementing a Central IRB Model in a Multicenter Research Network.

Burr JS, Johnson AR, Vasenina V, Bisping S, Coleman RW, Botkin JR, Dean JM.

Ethics Hum Res. 2019 May;41(3):23-28. doi: 10.1002/eahr.500016.

PMID:
31108575
14.

Long-term risk of cardiovascular disease in individuals with latent autoimmune diabetes in adults (UKPDS 85).

Maddaloni E, Coleman RL, Pozzilli P, Holman RR.

Diabetes Obes Metab. 2019 May 17. doi: 10.1111/dom.13788. [Epub ahead of print]

PMID:
31099472
15.

Correction: Focal Adhesion Kinase Targeting Using In vivo Short Interfering RNA Delivery in Neutral Liposomes for Ovarian Carcinoma Therapy.

Halder J, Kamat AA, Landen CN Jr, Han LY, Lutgendorf SK, Lin YG, Merritt WM, Jennings NB, Chavez-Reyes A, Coleman RL, Gershenson DM, Schmandt R, Cole SW, Lopez-Berestein G, Sood AK.

Clin Cancer Res. 2019 May 15;25(10):3194. doi: 10.1158/1078-0432.CCR-19-1132. No abstract available.

PMID:
31092618
16.

Pilot study of a ketogenic diet in relapsing-remitting MS.

Brenton JN, Banwell B, Bergqvist AGC, Lehner-Gulotta D, Gampper L, Leytham E, Coleman R, Goldman MD.

Neurol Neuroimmunol Neuroinflamm. 2019 Apr 12;6(4):e565. doi: 10.1212/NXI.0000000000000565. eCollection 2019 Jul.

17.

The endangered White's seahorse Hippocampus whitei chooses artificial over natural habitats.

Simpson M, Morris RL, Harasti D, Coleman RA.

J Fish Biol. 2019 May 9. doi: 10.1111/jfb.14002. [Epub ahead of print]

PMID:
31073989
18.

Department of Defense end-of-season influenza vaccine effectiveness estimates for the 2017-2018 season.

Coleman R, Eick-Cost AA, Hawksworth AW, Hu Z, Lynch L, Myers CA, DeMarcus L, Federinko S.

MSMR. 2018 Oct;25(10):16-20.

PMID:
31066571
19.

Extracorporeal Membrane Oxygenation Mortality in High-Risk Populations: An Analysis of the Pediatric Health Information System Database.

Coleman RD, Goldman J, Moffett B, Guffey D, Loftis L, Thomas J, Shekerdemian LS.

ASAIO J. 2019 Apr 15. doi: 10.1097/MAT.0000000000001002. [Epub ahead of print]

PMID:
31045920
20.

Comparison of risedronate versus placebo in preventing anastrozole-induced bone loss in women at high risk of developing breast cancer with osteopenia.

Sestak I, Blake GM, Patel R, Coleman RE, Cuzick J, Eastell R.

Bone. 2019 Jul;124:83-88. doi: 10.1016/j.bone.2019.04.016. Epub 2019 Apr 24.

21.

A Highly Effective and Ultra-Long-Acting Anti-Glaucoma Drug, with a Novel Periorbital Delivery Method.

Woodward DF, Wang JW, Coleman RA, Woodrooffe AJ, Clark KL, Stamer WD, Tao G, Fan S, Toris CB.

J Ocul Pharmacol Ther. 2019 Jun;35(5):265-277. doi: 10.1089/jop.2018.0126. Epub 2019 Apr 25.

PMID:
31025909
22.

Paclitaxel and Alisertib in Recurrent Ovarian Cancer-In Reply.

Falchook G, Coleman RL, Schilder RJ.

JAMA Oncol. 2019 Apr 25. doi: 10.1001/jamaoncol.2019.0562. [Epub ahead of print] No abstract available.

PMID:
31021370
23.

Public Health Surveillance Studies of Alcohol Industry Market and Political Strategies: A Systematic Review.

McCambridge J, Coleman R, McEachern J.

J Stud Alcohol Drugs. 2019 Mar;80(2):149-157.

PMID:
31014459
24.

Defective fatty acid oxidation in mice with muscle-specific acyl-CoA synthetase 1 deficiency increases amino acid use and impairs muscle function.

Zhao L, Pascual F, Bacudio L, Suchanek AL, Young PA, Li LO, Martin SA, Camporez JP, Perry RJ, Shulman GI, Klett EL, Coleman RA.

J Biol Chem. 2019 May 31;294(22):8819-8833. doi: 10.1074/jbc.RA118.006790. Epub 2019 Apr 11.

PMID:
30975900
25.

Metastatic bone disease: Pathogenesis and therapeutic options: Up-date on bone metastasis management.

D'Oronzo S, Coleman R, Brown J, Silvestris F.

J Bone Oncol. 2018 Nov 6;15:004-4. doi: 10.1016/j.jbo.2018.10.004. eCollection 2019 Apr. Review.

26.

GnRH-R-Targeted Lytic Peptide Sensitizes BRCA Wild-type Ovarian Cancer to PARP Inhibition.

Ma S, Pradeep S, Villar-Prados A, Wen Y, Bayraktar E, Mangala LS, Kim MS, Wu SY, Hu W, Rodriguez-Aguayo C, Leuschner C, Liang X, Ram PT, Schlacher K, Coleman RL, Sood AK.

Mol Cancer Ther. 2019 May;18(5):969-979. doi: 10.1158/1535-7163.MCT-18-0770. Epub 2019 Mar 29.

PMID:
30926640
27.

TOP: Time-to-Event Bayesian Optimal Phase II Trial Design for Cancer Immunotherapy.

Lin R, Coleman RL, Yuan Y.

J Natl Cancer Inst. 2019 Mar 29. pii: djz049. doi: 10.1093/jnci/djz049. [Epub ahead of print]

PMID:
30924863
28.

Microsatellite instability in endometrial cancer: New purpose for an old test.

Kurnit KC, Westin SN, Coleman RL.

Cancer. 2019 Mar 26. doi: 10.1002/cncr.32058. [Epub ahead of print] No abstract available.

PMID:
30913308
29.

An 11-Month-Old Male With Acute-Onset Left-Sided Facial Paralysis.

Posa M, Nestor K, Coleman R, Rajderkar D, Kelly MN.

Clin Pediatr (Phila). 2019 May;58(5):594-598. doi: 10.1177/0009922819837354. Epub 2019 Mar 22. No abstract available.

PMID:
30897949
30.

Treatment of patients with recurrent epithelial ovarian cancer for whom platinum is still an option.

Buechel M, Herzog TJ, Westin SN, Coleman RL, Monk BJ, Moore KN.

Ann Oncol. 2019 May 1;30(5):721-732. doi: 10.1093/annonc/mdz104.

PMID:
30887020
31.

Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial.

Konstantinopoulos PA, Barry WT, Birrer M, Westin SN, Cadoo KA, Shapiro GI, Mayer EL, O'Cearbhaill RE, Coleman RL, Kochupurakkal B, Whalen C, Curtis J, Farooq S, Luo W, Eismann J, Buss MK, Aghajanian C, Mills GB, Palakurthi S, Kirschmeier P, Liu J, Cantley LC, Kaufmann SH, Swisher EM, D'Andrea AD, Winer E, Wulf GM, Matulonis UA.

Lancet Oncol. 2019 Apr;20(4):570-580. doi: 10.1016/S1470-2045(18)30905-7. Epub 2019 Mar 14.

PMID:
30880072
32.

Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference.

Bast RC Jr, Matulonis UA, Sood AK, Ahmed AA, Amobi AE, Balkwill FR, Wielgos-Bonvallet M, Bowtell DDL, Brenton JD, Brugge JS, Coleman RL, Draetta GF, Doberstein K, Drapkin RI, Eckert MA, Edwards RP, Elias KM, Ennis D, Futreal A, Gershenson DM, Greenberg RA, Huntsman DG, Ji JXY, Kohn EC, Iavarone C, Lengyel ER, Levine DA, Lord CJ, Lu Z, Mills GB, Modugno F, Nelson BH, Odunsi K, Pilsworth JA, Rottapel RK, Powell DJ Jr, Shen L, Shih IM, Spriggs DR, Walton J, Zhang K, Zhang R, Zou L.

Cancer. 2019 Jun 15;125(12):1963-1972. doi: 10.1002/cncr.32004. Epub 2019 Mar 5.

PMID:
30835824
33.

Emotional experience in parents of children with Zellweger spectrum disorders: A qualitative study.

Bose M, Mahadevan M, Schules DR, Coleman RK, Gawron KM, Gamble MB, Roullet JB, Gibson KM, Rizzo WB.

Mol Genet Metab Rep. 2019 Feb 14;19:100459. doi: 10.1016/j.ymgmr.2019.100459. eCollection 2019 Jun.

34.

Neutral Lipid Storage Diseases as Cellular Model to Study Lipid Droplet Function.

Missaglia S, Coleman RA, Mordente A, Tavian D.

Cells. 2019 Feb 21;8(2). pii: E187. doi: 10.3390/cells8020187. Review.

35.

Phase III trials in ovarian cancer: The evolving landscape of front line therapy.

Naumann RW, Coleman RL, Brown J, Moore KN.

Gynecol Oncol. 2019 May;153(2):436-444. doi: 10.1016/j.ygyno.2019.02.008. Epub 2019 Feb 12. Review.

PMID:
30765149
36.

EZH2 cooperates with gain-of-function p53 mutants to promote cancer growth and metastasis.

Zhao Y, Ding L, Wang D, Ye Z, He Y, Ma L, Zhu R, Pan Y, Wu Q, Pang K, Hou X, Weroha SJ, Han C, Coleman R, Coleman I, Karnes RJ, Zhang J, Nelson PS, Wang L, Huang H.

EMBO J. 2019 Mar 1;38(5). pii: e99599. doi: 10.15252/embj.201899599. Epub 2019 Feb 5.

PMID:
30723117
37.

Heterotypic CAF-tumor spheroids promote early peritoneal metastatis of ovarian cancer.

Gao Q, Yang Z, Xu S, Li X, Yang X, Jin P, Liu Y, Zhou X, Zhang T, Gong C, Wei X, Liu D, Sun C, Chen G, Hu J, Meng L, Zhou J, Sawada K, Fruscio R, Grunt TW, Wischhusen J, Vargas-Hernández VM, Pothuri B, Coleman RL.

J Exp Med. 2019 Mar 4;216(3):688-703. doi: 10.1084/jem.20180765. Epub 2019 Feb 1.

38.

It takes a village: channeling fatty acid metabolism and triacylglycerol formation via protein interactomes.

Coleman RA.

J Lipid Res. 2019 Mar;60(3):490-497. doi: 10.1194/jlr.S091843. Epub 2019 Jan 25.

PMID:
30683668
39.

Urban blue: A global analysis of the factors shaping people's perceptions of the marine environment and ecological engineering in harbours.

Strain EMA, Alexander KA, Kienker S, Morris R, Jarvis R, Coleman R, Bollard B, Firth LB, Knights AM, Grabowski JH, Airoldi L, Chan BKK, Chee SY, Cheng Z, Coutinho R, de Menezes RG, Ding M, Dong Y, Fraser CML, Gómez AG, Juanes JA, Mancuso P, Messano LVR, Naval-Xavier LPD, Scyphers S, Steinberg P, Swearer S, Valdor PF, Wong JXY, Yee J, Bishop MJ.

Sci Total Environ. 2019 Mar 25;658:1293-1305. doi: 10.1016/j.scitotenv.2018.12.285. Epub 2018 Dec 20.

PMID:
30677991
40.

Endogenous Production of IL1B by Breast Cancer Cells Drives Metastasis and Colonization of the Bone Microenvironment.

Tulotta C, Lefley DV, Freeman K, Gregory WM, Hanby AM, Heath PR, Nutter F, Wilkinson JM, Spicer-Hadlington AR, Liu X, Bradbury SMJ, Hambley L, Cookson V, Allocca G, Kruithof de Julio M, Coleman RE, Brown JE, Holen I, Ottewell PD.

Clin Cancer Res. 2019 May 1;25(9):2769-2782. doi: 10.1158/1078-0432.CCR-18-2202. Epub 2019 Jan 22.

PMID:
30670488
41.

Presumed early ovarian cancer with isolated tumor cells in para-aortic sentinel nodes.

Uccella S, Fagotti A, Zannoni GF, Coleman RL.

Int J Gynecol Cancer. 2019 Jan;29(1):216-220. doi: 10.1136/ijgc-2018-000005. No abstract available.

PMID:
30640707
42.

Exploring and comparing adverse events between PARP inhibitors.

LaFargue CJ, Dal Molin GZ, Sood AK, Coleman RL.

Lancet Oncol. 2019 Jan;20(1):e15-e28. doi: 10.1016/S1470-2045(18)30786-1. Review.

PMID:
30614472
43.

Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04).

Coleman RE, Collinson M, Gregory W, Marshall H, Bell R, Dodwell D, Keane M, Gil M, Barrett-Lee P, Ritchie D, Bowman A, Liversedge V, De Boer RH, Passos-Coelho JL, O'Reilly S, Bertelli G, Joffe J, Brown JE, Wilson C, Tercero JC, Jean-Mairet J, Gomis R, Cameron D.

J Bone Oncol. 2018 Sep 27;13:123-135. doi: 10.1016/j.jbo.2018.09.008. eCollection 2018 Nov.

44.

Analysis of chain length, substitution patterns, and unsaturation of AM-404 derivatives as 20S proteasome stimulators.

Coleman RA, Muli CS, Zhao Y, Bhardwaj A, Newhouse TR, Trader DJ.

Bioorg Med Chem Lett. 2019 Feb 1;29(3):420-423. doi: 10.1016/j.bmcl.2018.12.030. Epub 2018 Dec 19.

PMID:
30587447
45.

Balancing biodiversity outcomes and pollution management in urban stormwater treatment wetlands.

Hale R, Swearer SE, Sievers M, Coleman R.

J Environ Manage. 2019 Mar 1;233:302-307. doi: 10.1016/j.jenvman.2018.12.064. Epub 2018 Dec 21.

PMID:
30583104
46.

Thioesterase superfamily member 2 promotes hepatic insulin resistance in the setting of glycerol-3-phosphate acyltransferase 1-induced steatosis.

Tillander V, Miniami A, Alves-Bezerra M, Coleman RA, Cohen DE.

J Biol Chem. 2019 Feb 8;294(6):2009-2020. doi: 10.1074/jbc.RA118.005184. Epub 2018 Dec 6.

PMID:
30523156
47.

Glycerol-3-phosphate acyltransferases 3 and 4 direct glycerolipid synthesis and affect functionality in activated macrophages.

Quiroga IY, Pellon-Maison M, Suchanek AL, Coleman RA, Gonzalez-Baro MR.

Biochem J. 2019 Jan 11;476(1):85-99. doi: 10.1042/BCJ20180381.

PMID:
30523059
48.

Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer.

Kurnit KC, Coleman RL, Westin SN.

Curr Treat Options Oncol. 2018 Nov 15;19(12):1. doi: 10.1007/s11864-018-0572-7. Review.

PMID:
30535808
49.

A randomized phase II study of letrozole vs. observation in patients with newly diagnosed uterine leiomyosarcoma (uLMS).

Slomovitz BM, Taub MC, Huang M, Levenback C, Coleman RL.

Gynecol Oncol Rep. 2018 Nov 16;27:1-4. doi: 10.1016/j.gore.2018.11.001. eCollection 2019 Feb.

Supplemental Content

Loading ...
Support Center